Attached files
| file | filename |
|---|---|
| EX-99.1 - Shengtai Pharmaceutical, Inc. | v205037_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): December 9, 2010 (December 8,
2010)
SHENGTAI
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in its Charter)
|
Delaware
|
000-51312
|
54-2155579
|
||
|
(State
or other jurisdiction of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
Changda
Road East
Development
District, Changle County
Shandong,
262400
The
People’s Republic of China
(Address
of principal executive offices, including zip code)
(86)
536-6295802
(Registrant’s
telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
| o |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
| o |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
| o |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01 Other
Events
On
December 8, 2010, Shengtai Pharmaceutical, Inc. (the “Company”) issued a press
release announcing that it has entered into a research and development
cooperation agreement with the Hubei University of Technology
(“HUT”). Through this joint program of research and development, the
Company and HUT anticipate using technology transfer and research between HUT
and the Company in the area of biological engineering technology to produce new
methods and technological advances for the Company. The press release is
attached as Exhibit 99.1 to this report on Form 8-K.
Item
9.01
Financial Statements and Exhibits
(d) Exhibits
|
Exhibit
No
|
Description
|
|
99.1
|
Press
Release of Shengtai Pharmaceutical, Inc., dated December 9,
2010.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
SHENGTAI
PHARMACEUTICALS, INC.
|
|
|
Dated:
December 9, 2010
|
|
|
By:
/s/ Qingtai
Liu
|
|
|
Name:
Qingtai Liu
|
|
|
Title:
Chief Executive Officer
|
3